Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis
Open Access
- 1 June 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 23 (6) , 1047-1054
Abstract
Background: Although numerous investigators have made efforts to assess prognostic biomarkers of prostate cancer, no biomarker has been recommended for clinical practice. Methods: According to REMARK (Reporting recommendations for tumor marker prognostic studies) and MISFISHIE (Minimum information specification for in situ hybridization and immunohistochemistry experiments) guidelines, the published articles of immunohistochemistry-based prognostic biomarkers on prostate cancer were extracted and pooled. Results: Ninety-three prognostic biomarkers from 92 high-quality cohort studies were included in this meta-analysis. Our analysis reveals some promising independent prognostic biomarkers, including Ki-67 [all-cause mortality (ACM) HR, 1.85; 95% confidence interval (CI), 1.06–3.25; PSM HR, 1.82; 95% CI, 1.42–2.34; DFS HR, 1.51; 95% CI, 1.31–1.75]; Bcl-2 (ACM HR, 2.14; 95% CI, 1.27–3.58; PSM HR, 1.61; 95% CI, 1.01–2.57; DFS HR, 3.86; 95% CI, 2.14–6.96); CD147 (ACM HR, 2.63; 95% CI, 1.19–5.81; DFS HR, 5.84; 95% CI, 3.41–9.99); COX-2 (PSM HR, 7.6; 95% CI, 0.7–80.1; DFS HR, 7.9; 95% CI, 2.62–23.83); ALDH1A1 (ACM HR, 1.73; 95% CI, 1.163–2.527; PSM HR, 1.05; 95% CI, 1.028–1.107), and FVIII (ACM HR, 1.76; 95% CI, 1.19–2.60; PSM HR, 1.01; 95% CI, 1.01–1.02). Conclusions: Our analysis identified a subset of biomarkers (Ki-67, Bcl-2, CD147, COX-2, ALDH1A1, and FVIII) that may have prognostic value for predicting the outcome of patients with prostate cancer. Impact: These reliable prognostic biomarkers will improve the clinical management of patients with prostate cancer. Cancer Epidemiol Biomarkers Prev; 23(6); 1047–54. ©2014 AACR.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic AttemptClinical Genitourinary Cancer, 2012
- An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomyCancer, 2012
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical ProstatectomyClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immunohistochemical Expression of BRCA1 and Lethal Prostate CancerCancer Research, 2010
- ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcomeLaboratory Investigation, 2009
- MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02Journal of Clinical Oncology, 2009
- Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesisThe Prostate, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007